Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eDC Therapy and Hypomethylating Agents in Elderly MDS
NCT04999943Phase 1Recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Jul 2021
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in myelodysplastic syndrome (MDS), sponsored by Academy of Military Medical Sciences. Primary endpoint: Overall Survival at 3 years. Started Jul 2021; status: recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04999943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999943.